Capricor Therapeutics, INC

Capricor Therapeutics announced that an FDA Advisory Committee voted against the effectiveness of Deramiocel for Duchenne muscular dystrophy cardiomyopathy, though the final decision rests with the FDA.

Capricor Therapeutics announced the publication of final one-year results from its HOPE-3 Phase 3 trial for Deramiocel in Duchenne muscular dystrophy in The Lancet, with an update to the statistical model for LVEF.

Capricor Therapeutics has entered into a lease agreement for a new 171,000 sq ft headquarters and manufacturing facility in San Diego, contingent on FDA approval.

Capricor Therapeutics announced that the FDA will hold an advisory committee meeting on July 29, 2026, to review the BLA for its DMD therapy, Deramiocel.

Capricor Therapeutics, Inc. held its Annual Meeting on June 4, 2026, where stockholders voted on director elections, auditor ratification, executive compensation, and amendments to the Certificate of Incorporation.

Capricor Therapeutics announced Q1 2026 financial results, highlighting the ongoing FDA review of its Deramiocel BLA for Duchenne muscular dystrophy with a PDUFA date of August 22, 2026, and positive HOPE-3 trial results.

Capricor Therapeutics has filed a lawsuit against Nippon Shinyaku alleging material breaches of their U.S. distribution agreement for Deramiocel.

Capricor Therapeutics received a Complete Response Letter from the FDA for its Deramiocel BLA, requiring additional clinical data, while reporting significantly increased net losses for the nine months ended September 30, 2025.

Capricor Therapeutics reported a significantly wider net loss in Q2 2025 and received a Complete Response Letter from the FDA for its Duchenne muscular dystrophy therapy, deramiocel, requiring additional clinical data.

Capricor Therapeutics announces Q1 2025 financial results and provides an update on its BLA submission for deramiocel, which has been granted Priority Review by the FDA.

Capricor Therapeutics reports a net loss of $12.6 million for the third quarter of 2024, while highlighting progress in its clinical programs and strategic partnerships.

Capricor Therapeutics reported its second quarter 2024 financial results, highlighting progress in its Duchenne muscular dystrophy program and exosome platform development.

Capricor Therapeutics' Deramiocel for Duchenne muscular dystrophy receives a new FDA PDUFA target action date of August 22, 2026, following positive Phase 3 HOPE-3 trial results and a resubmission addressing a prior Complete Response Letter.

Capricor Therapeutics' 10-K filing details the company's progress, including FDA acceptance of its BLA for deramiocel in DMD cardiomyopathy and priority review status.

Capricor Therapeutics' 10-K filing details its capital structure, stock information, and regulatory landscape, emphasizing its focus on cell and exosome-based therapies.

Capricor Therapeutics, Inc. reports a Form 4 filing detailing stock transactions by EVP, General Counsel Karen Krasney.

Capricor Therapeutics' Chief Financial Officer, Anthony Bergmann, has sold a significant number of company shares through a pre-arranged trading plan.

Karen Krasney, EVP and General Counsel of Capricor Therapeutics, Inc., reported transactions involving the purchase and sale of company common stock, executed under a Rule 10b5-1 trading plan.

Capricor Therapeutics' Chief Financial Officer, Anthony Bergmann, reported transactions involving the purchase and sale of company common stock and stock options.

Capricor Therapeutics' Chief Commercial Officer Michael T. Maurer received 80,000 stock options with an exercise price of $29.36.

Capricor Therapeutics' Chief Financial Officer, Anthony Bergmann, acquired 3,000 shares of common stock on May 18, 2026, at a price of $1.39 per share.

Capricor Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 4, 2026, detailing proposals for director elections, auditor ratification, executive compensation, and corporate governance amendments.

Capricor Therapeutics is soliciting proxies for its 2025 Annual Meeting of Stockholders, including proposals for director elections, ratification of the accounting firm, approval of the 2025 Equity Incentive Plan, and an advisory vote on executive compensation.

Capricor Therapeutics is holding its annual meeting on May 14, 2024, to vote on director elections, auditor ratification, executive compensation, and an increase in authorized common stock.

RA Capital Management and its affiliates have reported beneficial ownership of 3,014,183 shares, representing 5.2% of Capricor Therapeutics' outstanding common stock.

Suvretta Capital Management and its affiliates have reported a passive beneficial ownership of 6.6% in Capricor Therapeutics, Inc. common stock.

Tang Capital Management and affiliated entities have reported a 6.6% beneficial ownership stake in Capricor Therapeutics, Inc. as of January 16, 2026.

The Vanguard Group has filed an amendment to its Schedule 13G, disclosing a 4.82% beneficial ownership in Capricor Therapeutics Inc. common stock.

The Vanguard Group has reported a beneficial ownership of 5.04% in Capricor Therapeutics Inc., holding over 2.3 million shares of common stock.

The Vanguard Group has filed an amended Schedule 13G, disclosing its passive beneficial ownership of 4.95% of Capricor Therapeutics Inc.'s common stock as of March 31, 2025.